Targeting the organelle for radiosensitization in cancer radiotherapy.

Abstract

Radiotherapy is a well-established cytotoxic therapy for local solid cancers, utilizing high-energy ionizing radiation to destroy cancer cells. However, this method has several limitations, including low radiation energy deposition, severe damage to surrounding normal cells, and high tumor resistance to radiation. Among various radiotherapy methods, boron neutron capture therapy (BNCT) has emerged as a principal approach to improve the therapeutic ratio of malignancies and reduce lethality to surrounding normal tissue, but it remains deficient in terms of insufficient boron accumulation as well as short retention time, which limits the curative effect. Recently, a series of radiosensitizers that can selectively accumulate in specific organelles of cancer cells have been developed to precisely target radiotherapy, thereby reducing side effects of normal tissue damage, overcoming radioresistance, and improving radiosensitivity. In this review, we mainly focus on the field of nanomedicine-based cancer radiotherapy and discuss the organelle-targeted radiosensitizers, specifically including nucleus, mitochondria, endoplasmic reticulum and lysosomes. Furthermore, the organelle-targeted boron carriers used in BNCT are particularly presented. Through demonstrating recent developments in organelle-targeted radiosensitization, we hope to provide insight into the design of organelle-targeted radiosensitizers for clinical cancer treatment.

• Authors: Xiaoyan Sun, Linjie Wu, Lina Du, Wenhong Xu, Min Han
• Journal: Asian journal of pharmaceutical sciences (Asian J Pharm Sci) Vol. 19 Issue 2 Pg. 100903 (Apr 2024) ISSN: 2221-285X [Electronic] Netherlands
• PMID: 38590796 (Publication Type: Journal Article, Review)
• Copyright: © 2024 Shenyang Pharmaceutical University. Published by Elsevier B.V.